再生医学合作研究和许可协议（2019-2025）

Regenerative Medicine Collaboration and Licensing Deals 2019-2025

出版日期: 2025年11月01日 | 出版商:

Current Partnering | 英文 | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告分析了全球生物製药产业，并提供了2019年至2025年间1390项再生医学合作研究和授权协议的详细数据。

引言
过去几年再生医学合约
最活跃的再生医学承包商
依合约类型划分的再生医学合约
依治疗领域划分的再生医学合约
依行业划分的再生医学合约
再生医学的条款和条件合约
- 再生医学合约主要金额
- 再生医学合约预付款
- 再生医学合约里程碑付款
- 再生医学专利费率

第三章：主要再生医学合约

引言
依价值排名的顶级再生医学合同

第四章：最活跃的再生医学合约公司

引言
最活跃的再生医学合约公司
最活跃的再生医学合约公司简介

第五章：再生医学合约目录

引言
再生医学合约目录

第六章：依技术类型划分的再生医学合约

合约目录
合约目录 - 再生医学合约：依公司（A-Z）分类
合约目录 - 再生医学合约：依合约类型分类
合约目录 - 再生医学合约：依治疗领域分类
合约类型定义
关于 Biopharma Research Ltd
当前合作
当前协议
近期目前合作报告标题

简介目录

Product Code: CP2116

Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the regenerative medicine deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of regenerative medicine deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1390 regenerative medicine deals announced since 2016 including financial terms where available including links to online deal records of actual regenerative medicine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of regenerative medicine dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in regenerative medicine dealmaking since 2019.

Chapter 3 provides an overview of the leading regenerative medicine deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in regenerative medicine dealmaking with a brief summary followed by a comprehensive listing of regenerative medicine deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of regenerative medicine deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of regenerative medicine partnering deals signed and announced since Jan 2019. The chapter is organized by specific regenerative medicine technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in regenerative medicine deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Regenerative Medicine Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse regenerative medicine collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Regenerative Medicine Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of regenerative medicine trends and structure of deals entered into by leading biopharma companies worldwide.

Regenerative Medicine Collaboration and Licensing Deals includes:

Trends in regenerative medicine dealmaking in the biopharma industry
Directory of regenerative medicine deal records covering pharmaceutical and biotechnology
The leading regenerative medicine deals by value
Most active regenerative medicine licensing dealmakers
Regenerative Medicine Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in regenerative medicine dealmaking

2.1. Introduction
2.2. Regenerative medicine deals over the years
2.3. Most active regenerative medicine dealmakers
2.4. Regenerative medicine deals by deal type
2.5. Regenerative medicine deals by therapy area
2.6. Regenerative medicine deals by industry sector
2.7. Deal terms for regenerative medicine deals
- 2.7.1 Regenerative medicine deals headline values
- 2.7.2 Regenerative medicine deal upfront payments
- 2.7.3 Regenerative medicine deal milestone payments
- 2.7.4 Regenerative medicine royalty rates